Aristada

Aristada · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 24, 2030

~4.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (71)

Apr 6, 2039method-of-use (U-543)US 11273158
Apr 6, 2039method-of-use (U-543)US 11273158
Apr 6, 2039method-of-use (U-543)US 11273158
Apr 6, 2039method-of-use (U-543)US 11273158
Apr 6, 2039method-of-use (U-543)US 11273158
Apr 6, 2039method-of-use (U-543)US 12251381
Apr 6, 2039method-of-use (U-543)US 12251381
Apr 6, 2039method-of-use (U-543)US 12251381
Apr 6, 2039method-of-use (U-543)US 12251381
Apr 6, 2039method-of-use (U-543)US 12251381
Sep 8, 2035formulationUS 10016415
Aug 17, 2035formulationUS 10688091
Aug 17, 2035method-of-use (U-543)US 10849894
Aug 17, 2035formulationUS 11154552
Mar 19, 2035method-of-use (U-2402)US 10238651
Mar 19, 2035method-of-use (U-2402)US 10238651
Mar 19, 2035method-of-use (U-2402)US 10238651
Mar 19, 2035method-of-use (U-2402)US 10238651
Mar 19, 2035method-of-use (U-2402)US 10813928
Mar 19, 2035method-of-use (U-2983)US 10813928
Mar 19, 2035method-of-use (U-2983)US 10813928
Mar 19, 2035method-of-use (U-2983)US 10813928
Mar 19, 2035method-of-use (U-2402)US 11406632
Mar 19, 2035method-of-use (U-2402)US 11406632
Mar 19, 2035method-of-use (U-2402)US 11406632
Mar 19, 2035method-of-use (U-2402)US 11406632
Mar 19, 2035method-of-use (U-2402)US 9452131
Mar 19, 2035method-of-use (U-2402)US 9452131
Mar 19, 2035method-of-use (U-2402)US 9452131
Mar 19, 2035method-of-use (U-2402)US 9452131
Mar 19, 2035formulationUS 9526726
Mar 19, 2035formulationUS 9526726
Oct 24, 2033formulationUS 11097006
Oct 24, 2033formulationUS 11097006
Oct 24, 2033formulationUS 11097006
Oct 24, 2033formulationUS 11097006
Oct 24, 2033formulationUS 11969469
Oct 24, 2033formulationUS 11969469
Oct 24, 2033formulationUS 11969469
Oct 24, 2033formulationUS 11969469
Oct 24, 2033formulationUS 9193685
Oct 24, 2033formulationUS 9193685
Oct 24, 2033formulationUS 9193685
Oct 24, 2033formulationUS 9193685
Sep 19, 2033formulationUS 12311027
Sep 19, 2033formulationUS 12311027
Sep 19, 2033formulationUS 12311027
Sep 19, 2033formulationUS 12311027
Nov 7, 2032formulationUS 9034867
Nov 7, 2032formulationUS 9034867
Nov 7, 2032formulationUS 9034867
Nov 7, 2032formulationUS 9034867
Mar 19, 2032method-of-use (U-543)US 10226458
Mar 19, 2032method-of-use (U-543)US 10226458
Mar 19, 2032method-of-use (U-543)US 10226458
Mar 19, 2032method-of-use (U-543)US 10226458
Oct 26, 2030compositionUS 84315764.3y
Oct 26, 2030compositionUS 84315764.3y
Oct 26, 2030compositionUS 84315764.3y
Oct 26, 2030compositionUS 84315764.3y
Oct 26, 2030compositionUS 84315764.3y
Jun 24, 2030compositionUS 101129034.0y
Jun 24, 2030compositionUS 101129034.0y
Jun 24, 2030compositionUS 101129034.0y
Jun 24, 2030compositionUS 101129034.0y
Jun 24, 2030compositionUS 101129034.0y
Jun 24, 2030method-of-use (U-543)US 87962764.0y
Jun 24, 2030method-of-use (U-543)US 87962764.0y
Jun 24, 2030method-of-use (U-543)US 87962764.0y
Jun 24, 2030method-of-use (U-543)US 87962764.0y
Jun 24, 2030method-of-use (U-543)US 87962764.0y

aripiprazole lauroxil ER

indications

all catalysts(0)

News(0)

Patent cliff

patents (71)

Report a data issue

comments(0)

Trials studying aripiprazole lauroxil ER